Slingshot members are tracking this event:
Global Blood Therapeutics' Phase 2a of GBT440 HOPE-KIDS 1 treating Sickle cell disease in children age 6-17: Updated data due at ASH December 11, 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|GBT||Community voting in process|
Slingshot Insights Explained
Dec 11, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2a, Gbt440, Hope-kids 1